

EXHIBIT B
U.S. Application No. 09/328,296
Pennie & Edmonds LLP Docket No. 9632-005
Marked up Version of Claims April 18, 2001

1. (Amended) A molecule comprising [SEQ ID NO:3, SEQ ID NO:4,] SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (a) [immunospecifically] binds CD40, and (b) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110.

2. (Amended) The molecule of claim 1 comprising [the amino acid sequence of SEQ ID NO:2 or] the amino acid sequence of SEQ ID NO:7 [or the amino acid sequences of both SEQ ID NO:2 and NO:7].

8. (Amended) A [purified] protein comprising an amino acid sequence that has at least 95% identity to [SEQ ID NO:2 or] SEQ ID NO:7 as determined by use of the BLASTp computer program, which protein (a) [immunospecifically] binds CD40; and (b) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110.

9. (Amended) A [purified] protein, which protein (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (b) increases the binding of CD40 ligand to cell surface CD40 by at least 45%, and (c) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110.

21. (Amended) A pharmaceutical composition comprising:
- (a) a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) [immunospecifically] binds CD40, (ii) increases the

binding of CD40 ligand to cell surface CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, in an amount effective for the treatment or prevention of cancer; and

(b) a pharmaceutically acceptable carrier.

22. (Amended) A pharmaceutical composition comprising:

(a) a [purified] protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, in an amount effective for the treatment or prevention of cancer; and

(b) a pharmaceutically acceptable carrier.

23. (Amended) A pharmaceutical composition comprising:

(a) a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) [immunospecifically] binds CD40, (ii) increases the binding of CD40 ligand to cell surface CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, in an amount effective for activating or augmenting an immune response; and

(b) a pharmaceutically acceptable carrier.

24. (Amended) A pharmaceutical composition comprising:

- (a) a [purified] protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, in an amount effective for activating or augmenting an immune response; and
- (b) a pharmaceutically acceptable carrier.

36. (Amended) A pharmaceutical composition comprising in an amount effective for the treatment or prevention of cancer or an immune disorder, or for activating or augmenting an immune response: (a) a molecule that [immunospecifically] binds CD40, which molecule increases the binding of CD40 ligand to cell surface CD40; (b) CD40 ligand; and (c) a pharmaceutically acceptable carrier.